News

The Irish subsidiary of biopharmaceutical company Transition Therapeutics Inc. has finished patient enrollment for its phase 2 clinical study to assess a novel therapy for mild, moderate and severe Alzheimer’s disease. Transition Therapeutics Ireland Limited (TTIL) will now evaluate the neuropsychiatric drug candidate ELND005, expecting it…

According to medical specialists, research published last year stating that Vitamin B does not prevent Alzheimer’s disease is misleading, causing patients in early stages of the disease to miss out a potentially valuable treatment. Expert researchers and clinicians strongly criticized the previous study, saying that it is “inaccurate and misleading,” and are…

A team of Mexican scientists have developed a skin test that may provide an enhanced perspective on Alzheimer’s and Parkinson’s diseases, according to a study scheduled for presentation at The 67th American Academy of Neurology (AAN) Annual Meeting to be held April 18-25, 2015, at the Walter…

A collaboration between scientists from Dublin’s Trinity College (Ireland) and the University of Queensland (Australia) identified a compound able to inhibit an inflammatory process common to many diseases, including Alzheimer’s disease. The study entitled “A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases”…

Amarantus, a biotechnology company developing diagnostics in neurology and orphan drugs in neurology, ophthalmology, psychiatry and regenerative medicine, recently announced their abstract “The LymPro® Assay: A Biomarker For Alzheimer’s Disease Using Blood Samples From Clinically Diagnosed Alzheimer’s Disease And Cognitively Intact Subjects” has been accepted for poster presentation at the …

Researchers at the Uppsala University in Sweden recently found a molecular link between Type 2 Diabetes and Alzheimer’s disease based on a rare condition called amyloidosis that occurs in both conditions. The study is published in the American Journal of Pathology. Amyloidosis results from the accumulation of inappropriately…

Researchers at the Sunnybrook Research Institute in Toronto were able to reverse Alzheimer’s disease symptoms in mice with magnetic resonance (MR) imaging-guided focused ultrasound. Recent evidence has shown that MR imaging-guided focused ultrasound can briefly open the blood-brain barrier, allowing for an efficient transport of drugs…

In a new study entitled “The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory disease,” researchers report to have found a natural body producing metabolite – β-hydroxybutyrate (BHB) — capable of blocking NLRP3 inflammasome activation, a multi protein complex that promotes secretion of pro-inflammatory cytokines and is a key mediator…

A research team from the Karolinska Institutet in Sweden tested a new therapy for Alzheimer’s disease whereby patients received an implantable therapy that encourages the growth of a specific type of nerve cell that helps prevent the degradation of neurons. Alzheimer’s disease is driven by an early breakdown of…

Researchers at the Florida Campus of The Scripps Research Institute (TSRI) recently discovered a mechanism responsible for neuronal death that could be linked to several neurodegenerative diseases like Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis (ALS). Their findings entitled “Neuronal death induced by misfolded…